Talk:Aripiprazole: Difference between revisions

{{headerpanel|{{Approval}}}}

{{SummarySheet}}

'''Aripiprazole''' (branded as '''Abilify''', '''Aristada''' among others) is an atypical [[psychoactive class::antipsychotic]] approved for the treatment of schizophrenia, [[psychosis]], bipolar disorder, and along with an antidepressant to treat major depressive disorder.

Aripiprazole, developed by Otsuka Pharmaceutical and marketed as Abilify among others, was first approved in Japan in 2002 and subsequently in the United States. It was a novel development in the field of atypical [[antipsychotics]], primarily intended for schizophrenia and bipolar disorder treatment. Over time, its use expanded to include treatment of major depressive disorder and [[irritability]] in autism spectrum disorders.

Aripiprazole is a synthetic substance of the quinolinone class and is structurally distinct from other atypical antipsychotics. Its molecular formula is C_{23}H_{27}Cl_{2}N_{3}O_{2}, and it has a unique mechanism of action as a dopamine-serotonin system stabilizer.  

Aripiprazole's primary mechanism involves acting as a [[agonist|partial agonist]] at [[dopamine]] D2 and D3 receptors and [[serotonin|serotonin 5-HT1A]] receptors, while also serving as an [[antagonist]] at [[serotonin|serotonin 5-HT2A]] receptors. This dual action contributes to its efficacy in treating both the positive and negative symptoms of schizophrenia. It also exhibits moderate affinity for [[histamine]], [[adrenergic]], and muscarinic receptors, contributing to some of its side effects.

{{EffectStub}}

{{Preamble/SubjectiveEffects}}

}}

There are a limited number of experience reports for Aripiprazole given its medical usage, but some can be found in the [[experience index]] and on external platforms like Erowid.

{{toxicity}}

Although generally safe at therapeutic doses, Aripiprazole overdose can lead to severe symptoms like seizures, vomiting, and agitation. Long-term use may increase the risk of metabolic syndrome.

The lethal dosage of Aripiprazole is not well-established, but it is considered to have a high therapeutic index.

Aripiprazole has a low potential for abuse and addiction. Tolerance development is minimal.

Aripiprazole should not be combined with other substances that depress the central nervous system, such as alcohol, benzodiazepines, or opioids.

{{LegalStub}}

Aripiprazole is a prescription medication in many countries. Its legal status varies, but it is generally regulated and available only with a doctor's prescription.

* [[Responsible use]]

<references />

The 2016 [[NICE]] guidance for treating psychosis and schizophrenia in children and young people recommended aripiprazole as a second line treatment after [[risperidone]] for people between 15 and 17 who are having an acute exacerbation or recurrence of psychosis or schizophrenia.<ref>{{cite web |title=Psychosis and schizophrenia in children and young people: recognition and management {{!}} Guidance and guidelines {{!}} NICE |url=https://www.nice.org.uk/guidance/cg155/chapter/Recommendations |publisher=NICE |date=October 2016}}</ref> A 2014 NICE review of the depot formulation of the drug found that it might have a role in treatment as an alternative to other depot formulations of second generation antipsychotics for people who have trouble taking medication as directed or who prefer it.<ref>{{cite web |title=Schizophrenia: aripiprazole prolonged-release suspension for injection {{!}} Guidance and guidelines {{!}} NICE |url=https://www.nice.org.uk/advice/esnm39/chapter/Key-points-from-the-evidence |publisher=NICE |date=24 July 2013}}</ref>

[[Category:Psychoactive substance]][[Category:Proofread]][[Category:Approval]]